ES2165913T3 - Metodo continuo de trituracion de sustancias farmaceuticas. - Google Patents

Metodo continuo de trituracion de sustancias farmaceuticas.

Info

Publication number
ES2165913T3
ES2165913T3 ES95919062T ES95919062T ES2165913T3 ES 2165913 T3 ES2165913 T3 ES 2165913T3 ES 95919062 T ES95919062 T ES 95919062T ES 95919062 T ES95919062 T ES 95919062T ES 2165913 T3 ES2165913 T3 ES 2165913T3
Authority
ES
Spain
Prior art keywords
agent
grinding media
milling chamber
particle size
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95919062T
Other languages
English (en)
Inventor
David A Czekai
Larry P Seaman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Application granted granted Critical
Publication of ES2165913T3 publication Critical patent/ES2165913T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775Nanosized powder or flake, e.g. nanosized catalyst
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/84Manufacture, treatment, or detection of nanostructure
    • Y10S977/888Shaping or removal of materials, e.g. etching
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/84Manufacture, treatment, or detection of nanostructure
    • Y10S977/895Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y10S977/896Chemical synthesis, e.g. chemical bonding or breaking
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/84Manufacture, treatment, or detection of nanostructure
    • Y10S977/90Manufacture, treatment, or detection of nanostructure having step or means utilizing mechanical or thermal property, e.g. pressure, heat
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915Therapeutic or pharmaceutical composition
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Disintegrating Or Milling (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN METODO CONTINUO PARA LA PREPARACION DE PARTICULAS DE TAMAÑO INFERIOR A LA MICRA DE UN AGENTE TERAPEUTICO O DIAGNOSTICO COMPRENDE LAS ETAPAS DE INTRODUCIR DE FORMA CONTINUA EL AGENTE Y MEDIO DE MOLTURACION RIGIDO EN UNA CAMARA DE MOLTURACION, PONER EN CONTACTO EL AGENTE CON EL MEDIO DE MOLTURACION MIENTRAS SE ENCUENTRA EN LA CAMARA PARA REDUCIR EL TAMAÑO DE PARTICULA DEL AGENTE, RETIRAR DE FORMA CONTINUA EL AGENTE Y EL MEDIO DE MOLTURACION DE LA CAMARA DE MOLTURACION, Y POSTERIORMENTE SEPARAR EL AGENTE DEL MEDIO DE MOLTURACION. EN UN ASPECTO PREFERIDO, EL MEDIO DE MOLTURACION ES UNA RESINA POLIMERICA QUE POSEE UN TAMAÑO DE PARTICULA MEDIO DE MENOS DE 300 {MI}M. EN OTRO ASPECTO PREFERIDO, EL AGENTE, EL MEDIO DE MOLTURACION Y UN MEDIO DE DISPERSION LIQUIDO SE INTRODUCEN DE FORMA CONTINUA EN LA CAMARA DE MOLTURACION. EN UN ASPECTO ADICIONAL, EL AGENTE Y EL MEDIO DE MOLTURACION SE HACEN RECIRCULAR A TRAVES DE LA CAMARA DE MOLTURACION. EL METODO PERMITE EL USO DE MEDIO DE MOLTURACION FINO, POREJEMPLO DE UN TAMAÑO DE PARTICULA DE MENOS DE APROXIMADAMENTE 300 {MI}M, EN UN PROCESO DE MOLTURACION CONTINUO QUE PROPORCIONA PARTICULAS EXTREMADAMENTE FINAS DEL AGENTE, POR EJEMPLO PARTICULAS DE MENOS DE 100 NM DE TAMAÑO, EVITANDO AL MISMO TIEMPO PROBLEMAS, POR EJEMPLO LA OBTURACION DEL TAMIZ SEPARADOR, ASOCIADOS CON LOS PROCESOS CONOCIDOS ANTERIORMENTE QUE REQUIEREN LA SEPARACION DEL AGENTE DEL MEDIO DE MOLTURACION EN LA CAMARA DE MOLTURACION.
ES95919062T 1994-05-25 1995-05-08 Metodo continuo de trituracion de sustancias farmaceuticas. Expired - Lifetime ES2165913T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/249,787 US5718388A (en) 1994-05-25 1994-05-25 Continuous method of grinding pharmaceutical substances

Publications (1)

Publication Number Publication Date
ES2165913T3 true ES2165913T3 (es) 2002-04-01

Family

ID=22944996

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95919062T Expired - Lifetime ES2165913T3 (es) 1994-05-25 1995-05-08 Metodo continuo de trituracion de sustancias farmaceuticas.

Country Status (14)

Country Link
US (1) US5718388A (es)
EP (1) EP0804161B1 (es)
JP (1) JP3607294B2 (es)
AT (1) ATE208191T1 (es)
AU (1) AU2476195A (es)
CA (1) CA2190134C (es)
DE (1) DE69523781T2 (es)
DK (1) DK0804161T3 (es)
ES (1) ES2165913T3 (es)
IL (1) IL113851A (es)
MY (1) MY113569A (es)
PT (1) PT804161E (es)
TW (1) TW460297B (es)
WO (1) WO1995031973A1 (es)

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US6832735B2 (en) * 2002-01-03 2004-12-21 Nanoproducts Corporation Post-processed nanoscale powders and method for such post-processing
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6000646A (en) * 1998-03-16 1999-12-14 Ranne; Bethyl H. Double barrel media mill for grinding and dispersing particulate matter and pigment for paint, coatings, ink and other fluid pigment vehicles
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
ID29852A (id) * 1998-11-02 2001-10-18 Elan Corp Plc Cs Komposisi pelepasan modifikasi multi partikulasi
US7459283B2 (en) * 2002-02-04 2008-12-02 Elan Pharma International Limited Nanoparticulate compositions having lysozyme as a surface stabilizer
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
US6431478B1 (en) 1999-06-01 2002-08-13 Elan Pharma International Limited Small-scale mill and method thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
DK1313564T3 (da) 2000-04-26 2010-04-06 Elan Pharma Int Ltd Apparat til hygienisk våd formaling
EP1280604B1 (en) 2000-05-10 2008-03-19 Jagotec AG Media milling
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
SK287988B6 (sk) * 2001-01-26 2012-09-03 Schering Corporation Composition, oral dosage form and use thereof
US7100851B2 (en) * 2001-04-27 2006-09-05 Kansai Paint Co., Ltd. Method and apparatus for dispersing pigment in liquid medium
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
EP1401401B1 (en) * 2001-06-22 2005-03-30 Marie Lindner Method for high through put screening using a small scale mill or microfluidics
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US8403367B2 (en) 2001-08-02 2013-03-26 Eastman Kodak Company Authentication using near-field optical imaging
US6722699B2 (en) 2001-08-02 2004-04-20 Eastman Kodak Company Authentication using near-field optical imaging
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JP4464129B2 (ja) * 2001-09-19 2010-05-19 エラン ファーマ インターナショナル,リミティド ナノ粒子インスリン製剤
MXPA04002573A (es) * 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE371442T1 (de) * 2001-10-12 2007-09-15 Elan Pharma Int Ltd Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US20030152519A1 (en) * 2001-11-07 2003-08-14 Reinhard Koenig Methods for vascular imaging using nanoparticulate contrast agents
PL370889A1 (en) 2001-12-20 2005-05-30 Femmepharma, Inc. Vaginal delivery of drugs
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US6699963B2 (en) 2002-03-18 2004-03-02 The Procter & Gamble Company Grinding process for plastic material and compositions therefrom
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003082213A2 (en) * 2002-03-28 2003-10-09 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
DK1494649T3 (da) 2002-04-12 2012-04-10 Alkermes Pharma Ireland Ltd Nanopartikel-megestrolformuleringer
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル,リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
JP4878839B2 (ja) 2002-09-11 2012-02-15 エラン ファーマ インターナショナル,リミティド ゲル安定化ナノパーティクル活性物質組成物
EP1624958A2 (en) * 2002-10-09 2006-02-15 Novozymes A/S A method for improving particle compositions
US20040156895A1 (en) * 2002-11-12 2004-08-12 Elan Pharma International Ltd. Solid dosage forms comprising pullulan
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1578421A4 (en) 2003-01-02 2009-04-22 Femmepharma Holding Co Inc PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル,リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
KR20060007372A (ko) * 2003-03-06 2006-01-24 렌슬러 폴리테크닉 인스티튜트 실온에서 벌크 고체로부터 나노입자를 고속 발생시키는방법
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
DE602004018150D1 (de) * 2003-08-08 2009-01-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
US7618181B2 (en) * 2003-10-23 2009-11-17 Kansai Paint Co., Ltd. Method for dispersing pigment in liquid medium
US7879360B2 (en) * 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
EP1621200A1 (en) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
WO2006066063A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
EP1830902A2 (en) * 2004-12-30 2007-09-12 Cinvention Ag Combination comprising an agent providing a signal, an implant material and a drug
WO2006069419A1 (en) * 2004-12-31 2006-07-06 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
MX2007008212A (es) * 2005-01-06 2007-08-16 Elan Pharma Int Ltd Formulaciones de candesartan en nanoparticulas.
SI1836239T1 (sl) * 2005-01-13 2009-04-30 Cinv Ag Kompozitni materiali, ki vsebujejo ogljikove nanodelce
BRPI0606486A2 (pt) * 2005-01-24 2009-06-30 Cinv Ag materiais compósitos contendo metal
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
KR20070121759A (ko) * 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 비스포스포네이트 조성물
BRPI0608506A2 (pt) * 2005-03-18 2010-01-05 Cinv Ag processo para preparação de materiais metálicos porosos sinterizados
BRPI0609700A2 (pt) * 2005-03-23 2010-04-20 Elan Pharma Int Ltd formulações de corticosteróide nanoparticulado e antihistamina
CA2603084A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
WO2007086914A2 (en) * 2005-05-10 2007-08-02 Elan Pharma International, Limited Nanoparticulate clopidogrel formulations
AU2006344711A1 (en) * 2005-05-16 2008-01-24 Alkermes Pharma Ireland Limited Nanoparticulate and controlled release compositions comprising a cephalosporin
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
JP2008542397A (ja) * 2005-06-03 2008-11-27 エラン ファーマ インターナショナル リミテッド ナノ粒子メシル酸イマチニブ製剤
US20060292214A1 (en) * 2005-06-03 2006-12-28 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
JP2009517485A (ja) 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド セフジトレンを含むナノ粒子状および制御放出組成物
US20070059371A1 (en) * 2005-06-09 2007-03-15 Elan Pharma International, Limited Nanoparticulate ebastine formulations
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
MX2008000131A (es) * 2005-07-01 2008-04-04 Cinv Ag Dispositivos medicos que comprenden un material compuesto reticulado.
EA200800196A1 (ru) * 2005-07-01 2008-06-30 Синвеншен Аг Способ изготовления пористого композиционного материала
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
GB0516549D0 (en) * 2005-08-12 2005-09-21 Sulaiman Brian Milling system
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
WO2007045616A1 (en) * 2005-10-18 2007-04-26 Cinvention Ag Thermoset particles and methods for production thereof
MX2008006888A (es) 2005-11-28 2008-09-30 Marinus Pharmaceuticals Formulas y metodos para la manufactura y uso de la ganaxolona.
CA2635531C (en) 2005-12-29 2014-06-17 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
EP2001439A2 (en) * 2006-03-07 2008-12-17 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
KR20090015994A (ko) 2006-05-30 2009-02-12 엘란 파마 인터내셔널 리미티드 나노입자형 포사코나졸 제제
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
TW200820991A (en) * 2006-07-10 2008-05-16 Elan Pharma Int Ltd Nanoparticulate sorafenib formulations
EP2043623A4 (en) * 2006-07-12 2013-03-20 Elan Pharma Int Ltd NANOPARTICLE FORMULATIONS OF MODAFINIL
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
EP2104473A1 (en) * 2007-01-19 2009-09-30 Cinvention Ag Porous, non-degradable implant made by powder molding
US20080213742A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system
US20080206862A1 (en) * 2007-02-28 2008-08-28 Cinvention Ag High surface cultivation system bag
US20080206735A1 (en) * 2007-02-28 2008-08-28 Cinvention Ag High surface cultivation system with surface increasing substrate
EP2129766A2 (en) * 2007-02-28 2009-12-09 Cinvention Ag High surface cultivation system with filler
JP2011520779A (ja) * 2008-03-21 2011-07-21 エラン・ファルマ・インターナショナル・リミテッド イマチニブの部位特異的送達のための組成物および使用の方法
US8802075B2 (en) 2009-02-18 2014-08-12 Eyeon Particle Sciences Llc Bi-functional co-polymer use for opthalmic and other topical and local applications
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
AU2010254180B2 (en) 2009-05-27 2015-08-27 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
EP2442650B1 (en) 2009-06-12 2015-08-26 Cynapsus Therapeutics Inc. Sublingual apomorphine
HUP0900384A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
AU2010261509A1 (en) 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanoparticulate telmisartan compositions and process for the preparation thereof
HUP0900376A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
WO2010146407A1 (en) 2009-06-19 2010-12-23 Nanoform Hungary Ltd. Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
JP2013510092A (ja) 2009-11-05 2013-03-21 レクシコン ファーマシューティカルズ インコーポレイテッド がんの治療のためのトリプトファンヒドロキシラーゼ阻害剤
JP2013519673A (ja) 2010-02-10 2013-05-30 レクシコン ファーマシューティカルズ インコーポレイテッド 転移性骨疾患の治療のためのトリプトファンヒドロキシラーゼ阻害剤
PL2560624T3 (pl) 2010-04-23 2019-01-31 Kempharm, Inc. Formulacja terapeutyczna do zmniejszania skutków ubocznych leku
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
HUP1000327A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Composition containing nanostructured ezetibime and process for it's preparation
HUP1000325A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
EP2618818A4 (en) 2010-09-22 2014-10-29 Map Pharmaceuticals Inc CORTICOSTEROID PARTICLES AND METHOD FOR PRODUCING THE SAME
DE102010052656A1 (de) * 2010-11-26 2012-05-31 Netzsch-Feinmahltechnik Gmbh Hydraulische Mahlkugel Zu- und Abfuhr für Rührwerkskugelmühlen
AU2011343429B2 (en) 2010-12-16 2016-10-20 Sunovion Pharmaceuticals Inc. Sublingual films
EP2768481A4 (en) 2011-10-21 2015-07-08 Subhash Desai COMPOSITIONS TO REDUCE SIDE EFFECTS
WO2013074988A1 (en) 2011-11-17 2013-05-23 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
SG10201703243QA (en) * 2012-02-28 2017-06-29 Iceutica Holdings Inc Inhalable pharmaceutical compositions
WO2013148978A1 (en) 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP3808339A1 (en) 2012-05-03 2021-04-21 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP2016508447A (ja) * 2013-02-28 2016-03-22 サン・ケミカル・コーポレーション 連続的微細メディア含有粉砕プロセス
KR101741344B1 (ko) 2013-06-28 2017-05-29 렉산 파마슈티컬스, 인코포레이티드 피페라진 화합물의 나노미립자 조성물 및 제제
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HU231309B1 (hu) 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
US20150343453A1 (en) * 2014-05-28 2015-12-03 NanoCentrix L.L.C. Fluid energy media mill system and method
EP3508196B1 (en) 2014-08-18 2021-07-14 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
WO2016172095A1 (en) 2015-04-21 2016-10-27 Cynapsus Therapeutics, Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
WO2016178876A2 (en) 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
WO2017143017A1 (en) 2016-02-17 2017-08-24 Alkermes Pharma Ireland Limited Compositions of multiple aripiprazole prodrugs
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
LT3513809T (lt) 2016-09-13 2022-05-10 Kyowa Kirin Co., Ltd. Medicininė kompozicija, apimanti tivozanibą
US20210060051A1 (en) 2017-12-27 2021-03-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
US20230339880A1 (en) 2019-10-11 2023-10-26 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
CN114828889A (zh) 2019-12-06 2022-07-29 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
EP3928772B1 (en) 2020-06-26 2024-06-19 Algiax Pharmaceuticals GmbH Nanoparticulate composition
CN112427096B (zh) * 2020-10-19 2022-01-28 上海旭军机械有限公司 一种纳米材料的研磨设备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2595117A (en) * 1950-03-08 1952-04-29 Smidth & Co As F L Method and apparatus for grinding
ES293103A1 (es) * 1962-11-12 1964-03-16 Aziende Colori Naz Affini Acna S P A Procedimiento para la preparación de quinacridona en forma de pigmento
US3713593A (en) * 1970-08-11 1973-01-30 Freeport Sulphur Co Fine media milling process
SU514627A1 (ru) * 1972-07-19 1976-05-25 Институт Биохимии И Физиологии Микроорганизмов Ан Ссср Дезинтегратор дл микроорганизмов
US4860957A (en) * 1988-03-29 1989-08-29 Lidstroem Lars Treatment of middlings
JPH02132162A (ja) * 1988-11-11 1990-05-21 Showa Shell Sekiyu Kk 微小ジルコニア焼成ボールによる顔料の分散方法
US5174512A (en) * 1988-12-16 1992-12-29 Snamprogetti S.P.A. Grinding process and a continuous high-capacity micronizing mill for its implementation
JPH02196719A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
JPH04166246A (ja) * 1990-10-31 1992-06-12 Matsushita Electric Ind Co Ltd 媒体撹拌ミル及び粉砕方法
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
JPH05253509A (ja) * 1991-05-08 1993-10-05 Fuaimatetsuku:Kk 流通式媒体攪拌超微粉砕機
JPH05253512A (ja) * 1992-03-11 1993-10-05 Chuo Kakoki Kk 粉粒体又はスラリーの処理用媒体
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances

Also Published As

Publication number Publication date
JPH10500593A (ja) 1998-01-20
US5718388A (en) 1998-02-17
CA2190134A1 (en) 1995-11-30
TW460297B (en) 2001-10-21
DK0804161T3 (da) 2002-03-04
PT804161E (pt) 2002-04-29
EP0804161B1 (en) 2001-11-07
WO1995031973A1 (en) 1995-11-30
DE69523781T2 (de) 2002-06-13
JP3607294B2 (ja) 2005-01-05
DE69523781D1 (de) 2001-12-13
AU2476195A (en) 1995-12-18
IL113851A (en) 1999-12-22
MY113569A (en) 2002-04-30
IL113851A0 (en) 1995-08-31
CA2190134C (en) 2005-03-08
ATE208191T1 (de) 2001-11-15
EP0804161A1 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
ES2165913T3 (es) Metodo continuo de trituracion de sustancias farmaceuticas.
AU2550195A (en) Method of grinding pharmaceutical substances
CA2237310A1 (en) Process for separation and recovery of waste carpet components
PL323444A1 (en) Method of and apparatus for elestrostatically charging particles suspended in fluid gaseous medium and separating them therefrom
CA2182786A1 (en) Process for the production of particles or powders
CA2166301A1 (en) Method and apparatus for the formation of particles
AU2800395A (en) Method and apparatus for the formation of particles
ATE188391T1 (de) Methode und vorrichtung zur flüssigkeitschromatographie
WO2002045691A3 (en) Laboratory scale milling process
CA2045768A1 (en) Blast cleaning wet media feed and separation system
EP0853065A3 (en) Processing of ceramic materials
PL307354A1 (en) Treating apparatus
ATE180708T1 (de) Verfahren und anlage zur aufwertung von bei zerkleinerungsprozessen entstehenden heterogenen stoffgemischen
NO174282C (no) Fremgangsmåte til fremstilling av faste fine partikler
KR960700819A (ko) 지르코늄 실리케이트 연마 매체 및 분쇄 방법(zirconium silicate grinding medium and method of milling)
EP0997196A3 (en) Method of and apparatus for grinding material
WO1982004202A1 (fr) Dispositif de traitement de petrole
HUT60643A (en) Method for filtering the dust content of air and air-filtering insert
JPS59154149A (ja) 固体粒子の粉砕法
HU903176D0 (en) Liquid filter for separation of solid impurities, agglomerated grains of suspensions and other particles formed by settling out in liquids
JPS60250098A (ja) 石炭の脱灰法

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 804161

Country of ref document: ES